Company Overview and News

20
TTNP / Titan Pharmaceuticals, Inc. AMENDMENT NO. 2 TO FORM S-1

2018-09-12 sec.gov - 1
tv502115-s1a - block - 3.7560036s TABLE OF CONTENTS
TTNP

19
TTNP / Titan Pharmaceuticals, Inc. null

2018-09-11 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C0Y(# @;V)J#3P\+TQI;[email protected](O5'EP92]84F5F+U=;,2 R(#%=/CYS=')E86T-"FC>8F)[email protected] M8F#R!!(,4X [email protected](")-A!Q"<[email protected],@609&=.(_XZ0_ $& +5;!N,- M"F5N9'-T
TTNP

19
TTNP / Titan Pharmaceuticals, Inc. null

2018-09-11 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C0Q(# @;V)J#3P\+TQI;F5A
TTNP

20
TTNP / Titan Pharmaceuticals, Inc. FORM 8-K (Current Report)

2018-09-10 sec.gov - 1
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON
TTNP

19
TTNP / Titan Pharmaceuticals, Inc. FWP

2018-09-10 sec.gov
Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Registration No. 333-226841 September 10, 2018 We have file
TTNP

19
Overvalued Titan Pharmaceuticals Sells Convertible Securities

2018-09-05 seekingalpha
The company is selling several new convertible securities, which will increase the dilution risk for shareholders.
TTNP

24
TTNP / Titan Pharmaceuticals, Inc. FORM 8-K (Current Report)

2018-09-04 sec.gov - 5
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
TTNP

20
TTNP / Titan Pharmaceuticals, Inc. FREE WRITING PROSPECTUS

2018-09-04 sec.gov - 1
TITAN PHARMACEUTICALS CORPORATE PRESENTATION | SEPTEMBER 2018 © 2018 TITAN PHARMACEUTICALS INC. Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Registration No. 333 - 226841 September 4, 2018
TTNP

19
TTNP / Titan Pharmaceuticals, Inc. AMENDMENT NO. 1 TO FORM S-1

2018-08-30 sec.gov
tv501058-s1a - block - 3.5260344s TABLE OF CONTENTS
TTNP

19
TTNP / Titan Pharmaceuticals, Inc. FORM 8-K (Current Report)

2018-08-17 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
TTNP

23
Spring Bank Pharmaceuticals, Inc. Appoints Scott Smith to its Board of Directors

2018-08-16 globenewswire - 2
HOPKINTON, Mass., Aug. 16, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that it has added Scott Smith as an independent member of its Board of Directors to replace Jonathan Bates, who is stepping down from his role as a director after a long period of service to the company.
CELGZ SBPH CELG TTNP

19
TTNP / Titan Pharmaceuticals, Inc. FORM S-1

2018-08-14 sec.gov
tv500779-s1 - none - 4.1378542s TABLE OF CONTENTS
TTNP

19
TTNP / Titan Pharmaceuticals, Inc. 10-Q (Quarterly Report)

2018-08-14 sec.gov
UNITED STATES SECURITIES AND EXCHANGE CO
TTNP

19
TTNP / Titan Pharmaceuticals, Inc. FORM 8-K (Current Report)

2018-08-08 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
TTNP

TTNP: Titan Pharmaceuticals Analysis and Research Report

2018-09-14 - Asif

Overview Titan Pharmaceuticals is a pharmaceutical company developing proprietary therapeutics for the treatment of serious medical disorders. The company's product development programs utilize its proprietary long-term drug delivery platform, ProNeura™, and focus primarily on innovative treatments for select chronic diseases for which steady state delivery of a drug provides an efficacy and/or safety benefit. Probuphine®, its first product candidate based on the ProNeura platform, was approved by the FDA in May 2016 for the maintenance treatment of opioid dependence in patients who are stable on low to moderate doses of daily sublingual buprenorphine treatment. The company licensed development and commercialization rights of Probuphine for the U.S. and Canadian markets to Braeburn Pharmaceuticals, Inc., or Braeburn. In the first quarter of 2017, Braeburn commenced a full commercial launch of the product. However, as with the launch of any new method of medical treatment ...

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 888314309